CLEVELAND, Oct. 9, 2018 /PRNewswire/ -- ViewRay, Inc.
(NASDAQ: VRAY) announced today that the Company will hold a meeting
for investors and analysts on Monday,
October 22, 2018, during the annual meeting of the American
Society for Radiation Oncology (ASTRO) in San Antonio, TX.
The meeting will include a brief company update from
Scott Drake, President and Chief
Executive Officer of ViewRay, followed by presentations from
Louis B. Harrison, M.D., FASTRO,
Chair and Senior Member, Department of Radiation Oncology at
Moffitt Cancer Center and Michael L.
Steinberg, M.D., Professor and Chair, Department of
Radiation Oncology at the David Geffen School of Medicine at
UCLA.
Dr. Harrison will discuss the opportunity for MRI-guided
radiotherapy in the treatment of cancer and its potential
contribution to personalizing radiation therapy. Dr. Steinberg will
share UCLA's experience with MRI-guided
radiotherapy using the MRIdian System, including adaptive radiation
therapy, emerging functional imaging capabilities of the system,
and economic modeling leading to cost effectiveness. Breakfast will
be served at the meeting.
|
Event:
|
ViewRay Investor
& Analyst Meeting
|
|
Date:
|
Monday, October 22,
2018
|
|
Time:
|
7:00 – 9:00 a.m.
CT
|
|
Location:
|
Omni La Mansión Del
Rio, 112 College Street, San Antonio,
TX
|
As space is limited, please RSVP to Kaitlyn Brosco at kbrosco@theruthgroup.com if
you wish to attend the live event.
An audio webcast of the presentation will be available on the
investor relations section of ViewRay's website at www.viewray.com.
A replay of the webcast will be available for 7 days after the date
of the presentation.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs,
manufactures and markets the MRIdian® radiation therapy
system. MRIdian is built upon a proprietary high-definition MR
imaging system designed from the ground up to address the unique
challenges and clinical workflow for advanced radiation oncology
helping to transform radiation therapy, resulting in improved
treatment outcomes that benefit both patients and health care
systems around the world. Unlike MR systems used in diagnostic
radiology, MRIdian's high-definition MR was purposely built to
deliver high-precision radiation without unnecessary beam
distortion, and consequently, help to mitigate skin toxicity and
other safety concerns that may otherwise arise when high magnetic
fields interact with radiation beams. ViewRay and MRIdian are
registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release
contains forward-looking statements. Statements in this press
release that are not purely historical are forward-looking
statements. These forward-looking statements are made as of the
date of this press release, and ViewRay assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents ViewRay files with the SEC available at
www.sec.gov, including the risk factors disclosed in ViewRay's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-to-host-investor--analyst-meeting-at-2018-astro-annual-meeting-in-san-antonio-300727533.html
SOURCE ViewRay, Inc.